[ET Net News Agency, 13 June 2019] CanSino Biologics Inc. (06185) said the company and
BIRD-C Gmbh (BIRD-C) entered into a research and development collaboration agreement,
pursuant to which the parties shall collaborate with one another to explore (i) Bacterial
Ghosts (BGs) as standalone adjuvant to the company's vaccines; and (ii) bacterial antigen
expressing directly in E. coli carrier BGs to produce new vaccines.
BIRD-C is a company with limited liability incorporated in Vienna, Austria and offers
solutions for delivery of biologically active substances, vaccines and adjuvants against
emerging and existing infectious and life threatening diseases with focus on BGs cancer
immunotherapy.
The company will work closely with BIRD-C to conduct all preclinical and clinical
studies of new vaccines, and be responsible for commercial manufacturing, sales and
marketing of the new vaccines. During the term of the collaboration agreement, the company
will have an exclusive worldwide permanent right (including all intellectual properties
owned, developed or acquired by BIRD-C) for any new vaccine expressed by BIRD-C using E.
coli BGs as carrier and a non-exclusive worldwide permanent rights (including all BIRD-C
IP rights) for using BGs as standalone adjuvants. (RC)